Illumina Co-Founder David Walt Has Sold $114 Million in ILMN Stock — Now Buying Quanterix
David Walt, co-founder of Illumina's core bead array technology and director at Quanterix, has sold $114 million in ILMN stock across 4,807 transactions — while recently buying $1.4 million of QTRX shares.
David Walt, the scientist who co-invented the bead array technology at the heart of Illumina (ILMN), has filed 4,807 insider transactions totaling $114 million in career sales — but his most recent activity tells a different story: he’s buying heavily into Quanterix (QTRX).
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $114.1M |
| Career Buy Value | $11.5M |
| Total Transactions | 4,807 |
| Last Transaction | 2026-01-02 |
| Shares Remaining | 1,872,890 (QTRX) |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-01-02 | Award | 1,215 | N/A | N/A (QTRX) |
| 2025-06-13 | Buy | 123,990 | $6.14 | $760,803 (QTRX) |
| 2025-06-12 | Buy | 36,010 | $6.23 | $224,166 (QTRX) |
| 2025-06-09 | Buy | 78,131 | $5.34 | $417,220 (QTRX) |
| 2025-06-06 | Buy | 131,869 | $5.43 | $716,576 (QTRX) |
Walt's 2025 activity is exclusively Quanterix. In June 2025 alone, he purchased 370,000 QTRX shares for approximately $2.1 million at prices between $5.34 and $6.23 per share. These are open-market purchases — not option exercises — signaling high-conviction buying in a $5-6 stock. He also receives quarterly director stock awards, accumulating 1.87 million shares total.
What It Means
Walt is a Tufts University professor and one of the key inventors behind Illumina's bead-based DNA sequencing technology, which helped make Illumina the dominant force in genomics. His $114 million in ILMN sales across 4,807 transactions reflects decades of systematic liquidation as Illumina grew from a startup to a $20+ billion market cap company.
The Quanterix pivot is notable: Walt is a co-founder and board member of the ultra-sensitive protein detection company (Simoa technology). His $1.4 million in open-market QTRX purchases at $5-6 per share — combined with 1.87 million shares — represents a significant bet on a company trading at a fraction of its 2021 highs above $70. For an insider who systematically sold $114M of one genomics company, his aggressive buying of another suggests strong conviction in Quanterix's single-molecule detection platform.
What to Watch
- Whether Walt continues open-market QTRX purchases — his June 2025 buying spree was unusually aggressive for a director
- Quanterix's stock trajectory — trading near $5-6 versus 2021 highs above $70 creates significant upside potential if the business recovers
- Walt's remaining Illumina exposure (if any) — his Form 4 filings now show QTRX as his primary company
- The broader trend of biotech founders rotating capital from mature platforms to early-stage companies
Related Research
Explore all researchNational Bank of Canada grew to $109.99B in 2025Q4, added 110 new positions, and leaned harder into U.S. growth while keeping Canadian banks near the center.
Charles Schwab Investment Management kept Nvidia, Apple, and Microsoft at the top in Q4 2025 while quietly ramping Netflix and ServiceNow exposure beneath the surface.
UBS AM reported $472.97B in 2025Q4 13F value, with Nvidia, Microsoft and Apple forming the portfolio's core while Meta rose modestly.
Across covered utilities names, Q4 2025 institutional value clustered around regulated utilities rather than the whole sector evenly.
Robeco filed a fresh 2026Q1 13F with $70.16B of reported value, led by Nvidia, Apple, Microsoft, Alphabet, and Amazon.